Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. - Wikidata - awgldk - TriplyDB

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.

http://www.wikidata.org/entity/Q40634052

about

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline Simple Predictive Model for Identifying Patients with Chronic Hepatitis C and Hepatitis C Virus Genotype 4 Infection with a High Probability of Sustained Virologic Response with Peginterferon Alfa-2a/Ribavirin: Pooled Analysis of Data from Two Large New Therapies for Hepatitis C Virus Infection.Hepatitis C in a New Era: A Review of Current Therapies Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response Hepatitis B virus infection in Chinese patients with hepatitis C virus infection: prevalence, clinical characteristics, viral interactions and host genotypes: a nationwide cross-sectional study HCV management in resource-constrained countries.Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review.Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.Hepatitis C virus genotype 4: Genotype 1's little brother.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Treatment Options in Hepatitis C.Resistance Characterization of Ledipasvir and Velpatasvir in Hepatitis C Virus Genotype 4.Establishment of a platform for molecular and immunological characterization of the RNA-dependent-RNA-polymerase NS5B of an Egyptian HCV isolate.All-oral DAA therapy against HCV in HIV/HCV-coinfected subjects in real-world practice: Madrid-CoRe Findings.Recent update of the 2017 Korean Association for the Study of the Liver (KASL) treatment guidelines of chronic hepatitis C: comparison of guidelines from other continents, 2017 AASLD/IDSA and 2016 EASL.The emergence of NS5B resistance associated substitution S282T after sofosbuvir-based treatment.Clinical utility of ledipasvir/sofosbuvir in the treatment of adolescents and children with hepatitis C Expert opinion on the management of hepatitis C infection in Kuwait 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C

P2860

Q28076883-58495459-8865-4267-9BBE-49CAEA19E380 Q31121312-03940BD9-D184-4CC4-A50B-170B6883F210 Q33560181-825334DD-53E6-42BA-8F63-1E89DB88297C Q33585021-9C69E9EF-6B6F-4828-B7CE-65B97C821C27 Q36240269-B1C08312-B9C2-4F11-8945-8592E87B96DB Q37356018-67E2CA3A-C0FC-44AC-B04F-1D60CEA102CC Q38372939-2403428B-71E6-4CAB-87C6-4FC731D71357 Q38893244-328B7503-A42D-4A31-9A9B-F4F3499C34F4 Q39013086-A5520290-CB87-4D66-915C-9A0E4A046A5B Q39025320-ECD3C57E-0AA3-4878-830E-E49751B37638 Q39104215-8713079B-08CF-4DD9-8923-4DFE93270324 Q39112237-1C93D4A9-7C2C-4632-AE7D-26AC6468CE49 Q41923068-E1C6BA75-1F49-46C5-8469-65104D5B6F6D Q46257659-2DE18AD7-932B-427E-8155-4D8F57A7CCF8 Q47548361-79017AC9-5815-46C2-B28C-731770D45CCE Q54223871-7B1A4A2E-4438-4A51-8706-78A34EA06DD2 Q54943151-285B0008-CE21-49C2-B13D-3306F24935A4 Q56395991-4C2A94A6-FA60-4F1B-8CE1-62A6B8DFE741 Q57490314-63F9ED5E-65BA-40A0-8F72-A297D29D5FF2 Q58788714-0DE87D18-A0BA-496A-84ED-A891A4A798B8

P2860

Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.

http://www.wikidata.org/entity/Q40634052

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.

@en

type

label

Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.

@en

prefLabel

Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.

@en

P1433

Q40634052-5B30D92F-3770-48C8-852B-781998C2B918

P1476

Q40634052-1C637BF0-9BE8-4889-BDA0-34495A9E6E4A

P2093

Q40634052-006A2532-6BDE-4E4E-A3B7-398B2A5896E6

Q40634052-3A984061-F139-4011-97FA-08616FD73355

Q40634052-590C75CE-94A9-4C5E-9DB6-C5DC60E17F17

Q40634052-84C64DBD-68B2-4E4B-B032-3A0DE3371854

Q40634052-918DB2C6-08B9-4796-B6E4-86272A9434CA

Q40634052-A12E7D58-F415-4D8C-A844-044A66F82B39

Q40634052-CA304770-FE90-45AF-A596-2B7B30C93037

Q40634052-CD4E4530-EBA7-4664-B295-D3CE2FEF3797

Q40634052-FE2283D1-C2C4-4496-8E48-9AA28379851B

P2860

Q40634052-101B3D4A-0AF9-4DF1-9CDE-EAB95282B321

Q40634052-14EF5EEC-5FB5-417F-8BC7-2840028E1E76

Q40634052-1BC1A736-55FC-4AF6-A518-B65B69639F4D

Q40634052-20036607-E312-442E-9782-97AD0FE9C109

Q40634052-26C13C01-BA61-4171-A32C-5E674F7EB8D6

Q40634052-395064A4-D549-4B47-997F-5152C392BB22

Q40634052-396B28F9-7EA4-43CE-8E0C-D53F975D1213

Q40634052-3F265F0A-EA3B-43EE-8070-E2471F837812

Q40634052-44A084ED-8B5F-4424-8E44-57258D5E377E

Q40634052-4F978C57-B442-4483-B2AE-DB11F5B2E42B

P304

Q40634052-DABCED94-49A5-4849-B5AC-4229EA0306D3

P31

Q40634052-44FEB38A-A238-4D8C-A7CF-B777EAF1FF6A

P356

Q40634052-BBC8554F-E617-4C6E-A31E-135BBA64A2AF

P407

Q40634052-19AE07FC-1105-47EC-BF88-9FFAF27A98E4

P433

Q40634052-F83BFB11-ABBB-46EE-BACA-853C13568BB9

P478

Q40634052-2023A635-C814-44A4-9D53-B1A0C5F90063

P50

Q40634052-47324F25-2935-49C3-8AD9-E651F75E4730

Q40634052-A7CF9939-43C2-4EB0-9BB2-13CBF6729C7B

Q40634052-FDB18568-2944-4F97-8B8B-4681B8B1F994

P577

Q40634052-50E8697C-00E3-4280-85A0-259C2182F020

P698

Q40634052-17F5CD2E-87CE-4ACF-A27E-525C01B631E7

P921

Q40634052-F29373F4-3FCE-442C-BFDA-262C586DA608

P356

P1433

P1476

Ledipasvir plus sofosbuvir for ...... atitis C genotype 4 infection.

@en

P2093

Armand Abergel

http://www.w3.org/2001/XMLSchema#string

Deyuan Jiang

http://www.w3.org/2001/XMLSchema#string

Evguenia Svarovskaia

http://www.w3.org/2001/XMLSchema#string

Kathryn Kersey

http://www.w3.org/2001/XMLSchema#string

Phillip S Pang

http://www.w3.org/2001/XMLSchema#string

Sophie Metivier

http://www.w3.org/2001/XMLSchema#string

Steven J Knox

http://www.w3.org/2001/XMLSchema#string

Tarik Asselah

http://www.w3.org/2001/XMLSchema#string

Veronique Loustaud-Ratti

http://www.w3.org/2001/XMLSchema#string

P2860

Global epidemiology and genotype distribution of the hepatitis C virus infection

Sofosbuvir for previously untreated chronic hepatitis C infection

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.

A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C.

Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study.

Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

P304

1049-1056

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/HEP.28706

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

64

http://www.w3.org/2001/XMLSchema#string

P50

Evguenia Svarovskaia

Véronique Loustaud-Ratti

P577

2016-06-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27351341

http://www.w3.org/2001/XMLSchema#string

P921